Latest Period
Q4 2025
Security Snapshot
Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share (LRMR) Institutional Ownership
CUSIP: 517125100
13F Institutional Holders and Ownership History from Q2 2020 to Q1 2026
Institutions Reporting
135
Shares (Excl. Options)
72,424,903
Price
$3.81
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- LRMR on Nasdaq
- Shares outstanding
- 103,579,371
- Price per share
- $5.05
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 72,424,903
- Total reported value
- $275,932,718
- % of total 13F portfolios
- 0%
- Share change
- -12,638,977
- Value change
- -$38,772,040
- Number of holders
- 135
- Price from insider filings
- $5.05
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- LRMR - Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 517125100.
- 135 institutions reported positions in Q4 2025.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 135 to 27 between Q4 2025 and Q1 2026.
- Reported value moved from $275,932,718 to $17,857,170.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 135 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 517125100?
CUSIP 517125100 identifies LRMR - Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 517125100:
Significant Owners of Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share (LRMR) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Flynn James E | 34% | -3.9% | $123,052,785 | +$17,250,000 | 35,667,474 | +16% | Deerfield Management Company, L.P. | 27 Feb 2026 |
| Blue Owl Capital Holdings LP | 10% | $28,187,328 | 8,464,663 | Blue Owl Capital Holdings LP | 31 Dec 2025 | |||
| Opaleye Management Inc. | 4.8% | -23% | $15,412,500 | +$590,966 | 4,110,000 | +4% | Opaleye Management, Inc. | 29 Aug 2025 |
| MILLENNIUM MANAGEMENT LLC | 3.5% | -38% | $16,313,751 | -$6,036,988 | 3,625,278 | -27% | Millennium Management LLC | 31 Mar 2026 |
| BlackRock, Inc. | 4.8% | -6% | $7,175,619 | -$433,939 | 3,079,665 | -5.7% | BlackRock, Inc. | 31 Mar 2025 |
| GOLDMAN SACHS GROUP INC | 4.1% | $6,058,491 | 2,600,211 | THE GOLDMAN SACHS GROUP, INC. | 31 Mar 2025 |
As of 31 Dec 2025, 135 institutional investors reported holding 72,424,903 shares of Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share (LRMR). This represents 70% of the company’s total 103,579,371 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share (LRMR) together control 66% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. | 30% | 30,606,974 | 0% | 1.5% | $116,612,571 |
| Blue Owl Capital Holdings LP | 6.6% | 6,823,690 | +17% | 8% | $25,998,259 |
| MILLENNIUM MANAGEMENT LLC | 5% | 5,206,364 | +6.3% | 0.01% | $19,836,247 |
| BlackRock, Inc. | 3.6% | 3,681,603 | +10% | 0% | $14,026,908 |
| RTW INVESTMENTS, LP | 3% | 3,125,000 | 0% | 0.12% | $11,906,250 |
| VANGUARD GROUP INC | 2.9% | 3,046,216 | -1.3% | 0% | $11,606,083 |
| AIGH Capital Management LLC | 1.9% | 2,000,000 | +100% | 2.3% | $7,620,000 |
| Point72 Asset Management, L.P. | 1.4% | 1,461,028 | +19% | 0.01% | $5,566,517 |
| CITADEL ADVISORS LLC | 1.3% | 1,366,750 | -7.5% | 0% | $5,207,317 |
| GOLDMAN SACHS GROUP INC | 1.3% | 1,347,215 | -14% | 0% | $5,132,889 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1% | 1,093,323 | +6.9% | 0% | $4,166,238 |
| DAFNA Capital Management LLC | 0.91% | 939,164 | -8.6% | 0.83% | $3,578,215 |
| Alyeska Investment Group, L.P. | 0.9% | 927,821 | -51% | 0.01% | $3,534,998 |
| STATE STREET CORP | 0.88% | 911,925 | +2.2% | 0% | $3,474,434 |
| Woodline Partners LP | 0.77% | 800,850 | -51% | 0.01% | $3,051,239 |
| JANE STREET GROUP, LLC | 0.66% | 678,942 | +61% | 0% | $2,586,769 |
| Verition Fund Management LLC | 0.55% | 567,683 | 0% | 0.01% | $2,162,872 |
| Driehaus Capital Management LLC | 0.52% | 535,464 | 0% | 0.01% | $2,040,118 |
| AQR CAPITAL MANAGEMENT LLC | 0.48% | 502,251 | -11% | 0% | $1,913,576 |
| D. E. Shaw & Co., Inc. | 0.42% | 437,399 | 0% | $1,666,490 | |
| Caption Management, LLC | 0.4% | 415,294 | -68% | 0.07% | $1,582,270 |
| FEDERATED HERMES, INC. | 0.35% | 358,907 | +14886% | 0% | $1,367,435 |
| NORTHERN TRUST CORP | 0.34% | 356,775 | -5.7% | 0% | $1,359,312 |
| ExodusPoint Capital Management, LP | 0.33% | 344,246 | +111% | 0.01% | $1,311,577 |
| DIMENSIONAL FUND ADVISORS LP | 0.32% | 327,494 | +482% | 0% | $1,247,752 |
Institutional Holders of Larimar Therapeutics, Inc. - Common Stock, par value $0.001 per share (LRMR) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 3,966,020 | $17,857,170 | +$7,063,194 | $4.50 | 27 |
| 2025 Q4 | 72,424,903 | $275,932,718 | -$38,772,040 | $3.81 | 135 |
| 2025 Q3 | 85,496,565 | $274,794,131 | +$75,244,593 | $3.23 | 135 |
| 2025 Q2 | 62,321,311 | $180,120,860 | +$7,437,034 | $2.89 | 116 |
| 2025 Q1 | 60,827,153 | $131,864,050 | -$12,271,759 | $2.15 | 101 |
| 2024 Q4 | 63,434,614 | $245,492,888 | -$5,894,960 | $3.87 | 115 |
| 2024 Q3 | 64,329,070 | $421,287,622 | -$5,929,383 | $6.55 | 122 |
| 2024 Q2 | 65,308,461 | $473,379,696 | +$12,179,883 | $7.25 | 105 |
| 2024 Q1 | 63,594,662 | $482,627,362 | +$182,781,336 | $7.59 | 102 |
| 2023 Q4 | 39,456,509 | $179,551,948 | +$15,220,703 | $4.55 | 69 |
| 2023 Q3 | 38,745,394 | $153,032,401 | -$3,458,223 | $3.95 | 63 |
| 2023 Q2 | 39,027,692 | $120,194,716 | -$3,770,373 | $3.13 | 65 |
| 2023 Q1 | 38,462,442 | $174,244,129 | +$1,086,191 | $4.53 | 68 |
| 2022 Q4 | 38,766,976 | $160,093,910 | +$976,279 | $4.13 | 47 |
| 2022 Q3 | 38,715,175 | $123,902,000 | +$77,822,908 | $3.20 | 52 |
| 2022 Q2 | 14,391,311 | $28,222,000 | -$2,241,518 | $1.96 | 34 |
| 2022 Q1 | 15,257,103 | $61,778,000 | -$2,584,495 | $4.05 | 40 |
| 2021 Q4 | 14,567,301 | $157,170,000 | -$456,088 | $10.79 | 47 |
| 2021 Q3 | 14,519,322 | $167,488,004 | +$199,976 | $11.53 | 50 |
| 2021 Q2 | 14,543,964 | $142,828,000 | -$4,477,645 | $9.82 | 42 |
| 2021 Q1 | 14,110,404 | $206,147,000 | -$8,290,625 | $14.61 | 53 |
| 2020 Q4 | 14,252,270 | $305,135,000 | +$10,378,818 | $21.41 | 42 |
| 2020 Q3 | 13,625,016 | $206,745,000 | +$10,359,632 | $15.17 | 37 |
| 2020 Q2 | 12,953,044 | $166,142,000 | +$166,142,000 | $12.85 | 34 |